Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated malaria, but there is widespread resistance. At the time of this study, artemether-lumefantrine (AL) and chlorproguanil-dapsone (CPD), both multi-dose regimes, were considered possible alternatives to SP in Malawi. The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
BACKGROUND: High levels of patient adherence to antimalarial treatment are important in ensuring dru...
Abstract Background Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicate...
Background: Since November 2006, Coartem® (Artemether-Lumefantrine-ALu) replaced Sulphadoxine-Pyrime...
Adherence to multidosing is challenging worldwide. This study assessed the extent of adherence to mu...
BACKGROUND: Increasing access to and targeting of artemisinin-based combination therapy (ACT) is a k...
Background Based on the recommendations of the World Health Organization in 2004, Ghana changed her ...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Adherence to artemisinin-based combination therapies (ACTs) for malaria is important for effective ...
Research Article published by BioMed CentralBackground: Prompt diagnosis and effective treatment are...
Background: The impact of resistance to antimalarials is insidious and unless efficacy studies are c...
A follow-up study was conducted to determine the magnitude of and factors related to adherence to ar...
Article published in Clinical Infectious DiseasesThere are several problems associated with treatmen...
Background: Despite the advancement in malaria treatments and management; malaria morbidity and mort...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
BACKGROUND: High levels of patient adherence to antimalarial treatment are important in ensuring dru...
Abstract Background Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicate...
Background: Since November 2006, Coartem® (Artemether-Lumefantrine-ALu) replaced Sulphadoxine-Pyrime...
Adherence to multidosing is challenging worldwide. This study assessed the extent of adherence to mu...
BACKGROUND: Increasing access to and targeting of artemisinin-based combination therapy (ACT) is a k...
Background Based on the recommendations of the World Health Organization in 2004, Ghana changed her ...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Adherence to artemisinin-based combination therapies (ACTs) for malaria is important for effective ...
Research Article published by BioMed CentralBackground: Prompt diagnosis and effective treatment are...
Background: The impact of resistance to antimalarials is insidious and unless efficacy studies are c...
A follow-up study was conducted to determine the magnitude of and factors related to adherence to ar...
Article published in Clinical Infectious DiseasesThere are several problems associated with treatmen...
Background: Despite the advancement in malaria treatments and management; malaria morbidity and mort...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
BACKGROUND: High levels of patient adherence to antimalarial treatment are important in ensuring dru...